Drug Trial Radar · NCT07136181
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
Last checked: Nov 19, 2026Latest source record: Nov 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Nov 20, 2025
Primary completion
Mar 28, 2028
Study completion Aug 30, 2029
Sponsor
- Lead sponsor
- Novelwise Pharmaceutical CorporationIndustry
- Sponsor type
- Industry
- First posted
- Aug 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to find the best dose of an investigational drug called NBM-BMX for people with metastatic uveal melanoma, a type of eye cancer that has spread to other parts of the body. The study will help doctors learn about the side effects of NBM-BMX, how the drug is processed in the body, and whether it may slow down or shrink tumors. Participants will take NBM-BMX as a capsule by mouth twice daily on an empty stomach with at least six ounces (180 mL) of water. No food or drink (other than water) should be consumed for at least two hours after each dose. Participants will visit the clinic about once every week or two for exams and blood tests while taking NBM-BMX. After stopping treatment, a follow-up visit will occur about 30 days later. Treatment may continue as long as the cancer does not get worse and side effects remain manageable.
Conditions
- Metastatic Uveal Melanoma
- Uveal Melanoma, Metastatic
- Uveal Melanoma, Recurrent
- Eye Cancer, Intraocular Melanoma
- Eye Cancer
Interventions
NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.Drug
NBM-BMX is a small molecule inhibitor of HDAC8. The majority of metastasizing uveal melanoma (UM) cases are characterized by the presence of BAP1 mutations. However, as BAP1 mutations lead to a loss of function, therapeutic strategies have primarily focused on exploiting vulnerabilities resulting from BAP1 loss or targeting downstream effectors affected by the BAP1-deficient phenotype. In uveal melanocytes, the absence of BAP1 disrupts their differentiated cell identity, potentially contributing to the metastatic behavior observed in BAP1-mutant UM cells. This differentiation block in the melanocytic lineage is thought to be influenced, at least in part, by the activation of HDAC8 downstream, which leads to the repression of differentiation genes through acetylation of the histone H3K27 at the promoter and enhancers associated with these genes. Consequently, inhibiting HDAC8 could potentially reverse the differentiation block caused by the loss of BAP1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib: Incidence of dose-limiting toxicities (DLTs)Time frame: Time Frame: Cycle 1 (up to 28 days)
- Phase Ib: Maximum Tolerated Dose (MTD)Time frame: Cycle 1 (up to 28 days)
- Phase II: Objective Response Rate (ORR)Time frame: Assessed every 8-12 weeks from first dose; up to ~24 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Honor Health Resarch Institute
Scottsdale, Arizona · Recruiting
Sarah Cannon Research Institute (SCRI) - Denver HealthONE Location
Denver, Colorado · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.